Joel Lexchin, M.D., from York University in Toronto, reports that 71 drugs approved by the FDA from 2002 to 2014 for solid tumors have resulted in median gains in progression-free and overall survival of 2.5 and 2.1 months, respectively. He also points out that a similar study of solid cancer drugs within 10 years of EMA approval improved survival by slightly over a month.

Poll Question:
Do you think regulatory agencies should be required to provide stronger evidence of the clinical effectiveness of cancer drugs, including a greater emphasis on patient survival time?

Yes
79

No
10

Previous articleNovel Class of Molecules Destroys Cancer Cells While Protecting Healthy Ones
Next articleHuman Longevity and Cleveland Collaborate on Heart Disease Genomics